Padda Institute applies new low-carb guideline to chronic pain care

Dr. Gurpreet Singh Padda and the Padda Institute Center for Interventional Pain Management are using a newly published therapeutic carbohydrate reduction guideline to manage medication changes for chronic pain patients in St. Louis. The move matters because the first days of low-carb treatment can quickly alter blood pressure, blood sugar and sodium balance, especially in patients already taking multiple pain and diabetes drugs.

Why it matters: - Low-carb treatment can change blood sugar, blood pressure and fluid balance within days, which makes medication management a safety issue for chronic pain patients. - Pain patients often take several drugs at once, including diabetes medicines, blood pressure pills, NSAIDs, opioids and antidepressants used for pain. - The new guideline gives clinicians a shared playbook for adjusting those medicines early, before side effects or hypoglycemia occur.

What happened: - Dr. Gurpreet Singh Padda, MD, MBA, MHP, is applying a new Society of Metabolic Health Practitioners guideline at the Padda Institute Center for Interventional Pain Management in St. Louis. - The guideline, “A Delphi consensus-based guideline for the implementation of therapeutic carbohydrate reduction in metabolic disorders,” was published Oct. 2, 2026 in the Journal of Metabolic Health. - The Society of Metabolic Health Practitioners released the guideline as an update to its 2019 implementation guide. - Twenty-six of 28 clinicians and researchers voted in the final Delphi round. - All 18 statements in the guideline cleared the preset 70% threshold, and 15 were unanimous. - Dr. Padda holds the society’s Metabolic Health Practitioner credential.

The details: - The guideline cites the American Diabetes Association’s 2025 Standards of Care, which say low-carbohydrate and very-low-carbohydrate eating patterns can reduce A1C and the need for glucose-lowering medication. - Insulin doses are generally reduced immediately because the first two to three days carry the highest risk of severe low blood sugar. - Sulfonylureas and meglitinides are stopped at the start. - Blood pressure medicines are reviewed at the beginning of treatment and then every two to four weeks, with home blood pressure readings used to guide follow-up. - Adults with type 2 diabetes and stable glucose can often stop insulin once the dose falls below 10 units a day, after a C-peptide test confirms endogenous insulin production. - The guideline flags NSAIDs, narcotics, opiates and several antidepressants used for pain, including amitriptyline, as drugs that can worsen low sodium during the low-carb transition. - The same sodium and water loss that can cause start-up headache and leg cramps can compound those medication risks. - The guideline also names joint pain and migraine as conditions that may improve as metabolic health improves, so medicines used for those problems should also be reviewed. - The authors describe the guideline as a structured Delphi consensus based on a targeted, non-systematic review of human studies, without a formal evidence-grading framework. - The document includes medication adjustments, electrolyte targets of 2 to 3 grams of sodium a day for most people during adaptation, baseline lab tests and cautions for kidney disease, pregnancy, gout and gallbladder disease. - The Padda Institute has published a patient guide for people with chronic pain at the patient guide. - The guideline is open access at the full paper, and the society has summarized it at the society summary. - Dr. Padda directs a physician-led chronic pain practice that serves the St. Louis region, Missouri and Illinois. - The practice says it uses an interventional-first approach with image-guided diagnosis and treatment and treats chronic pain as a metabolic disease. - Dr. Padda is board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine.

Between the lines: - Dr. Padda is extending a metabolic guideline into pain care, which suggests a broader view of chronic pain as a condition tied to inflammation, insulin and tissue health. - He says about 93% of chronic pain in his practice involves metabolic dysfunction, while national metabolic health remains low under stricter criteria applied after 2021. - The clinic says under 1% of its chronic pain population meets those tighter metabolic-health criteria, but those are practice-reported figures and not trial outcomes. - The guideline is not a chronic pain study, but it gives pain clinicians a citable framework for medication changes that often get overlooked when patients start low-carb eating. - Dr. Padda said the key issue is that the diet works quickly while many prescriptions do not, making supervision on day one important.

What's next: - The Padda Institute is positioning the guideline as a practical tool for patients and physicians managing chronic pain alongside metabolic disease. - The open-access publication and patient guide make it easier for other clinicians to adopt the same medication-adjustment approach. - More pain practices may use the guideline to reassess blood pressure drugs, diabetes medicines and pain-related prescriptions when patients start therapeutic carbohydrate reduction.

The bottom line: - The new guideline turns low-carb eating from a diet change into a closely managed medication protocol, and Dr. Padda is betting that approach can make chronic pain care safer and more effective.